MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VVOS had -$1,315K decrease in cash & cash equivalents over the period. -$4,078K in free cash flow.

Cash Flow Overview

Change in Cash
-$1,315K
Free Cash flow
-$4,078K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Proceeds from issuance of warran...
    • Proceeds from issuance of pre-fu...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Proceeds from exercise of warran...
    • Accounts receivable
    • Others

Cash Flow
2025-09-30
2025-06-30
Net loss
-5,399 -8,877
Stock-based compensation expense
55 559
Paid-in-kind interest expense on promissory note
100 -
Depreciation and amortization
384 483
Fair value of common stock issued for services
-0
Accounts receivable
501 269
Non-cash interest expense on promissory note
-100
Operating lease liabilities, net
-7 -67
Prepaid expenses and other current assets
-130 -98
Deposits
16 -64
Accounts payable
340 608
Accrued expenses
442 -127
Other liabilities
358 646
Fair value of warrants issued for services
-0
Contract liability
53 -508
Net cash used in operating activities
-4,161 -7,290
Payment for acquisition, net of excess cash of 865
0 5,135
Acquisitions of property and equipment
-83 893
Net cash used in investing activities
83 -6,028
Proceeds from issuance of debt
-417 9,642
Proceeds from issuance of common stock
2,428 347
Proceeds from issuance of warrants
1,699 -
Proceeds from issuance of pre-funded warrants
609 -
Proceeds from exercise of warrants
-833 1,699
Payments for issuance costs
0 837
Reduction of finance lease liability
17 -
Proceeds from issuance of pre-funded warrants
-609
Reduction of debt liability
97 -
Net cash provided by financing activities
2,763 11,460
Net increase (decrease) in cash and cash equivalents
-1,315 -1,858
Cash and cash equivalents at beginning of period
6,260 -
Cash and cash equivalents at end of period
3,087 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock$2,428K Proceeds from issuance ofwarrants$1,699K Acquisitions of property andequipment-$83K Proceeds from issuance ofpre-funded warrants$609K Net cash provided byfinancing activities$2,763K Net cash used ininvesting activities$83K Canceled cashflow$1,973K Net increase(decrease) in cash and cash...-$1,315K Canceled cashflow$2,846K Accrued expenses$442K Depreciation andamortization$384K Other liabilities$358K Accounts payable$340K Prepaid expenses andother current assets-$130K Paid-in-kind interestexpense on promissory...$100K Stock-based compensationexpense$55K Contract liability$53K Proceeds from exercise ofwarrants-$833K something is missing-$609K Proceeds from issuance ofdebt-$417K Reduction of debtliability$97K Reduction of finance leaseliability$17K Net cash used inoperating activities-$4,161K Canceled cashflow$1,862K Net loss-$5,399K Accounts receivable$501K Deposits$16K Operating leaseliabilities, net-$7K

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (VVOS)